Search

Your search keyword '"Ilhan, Harun"' showing total 480 results
Start Over Author "Ilhan, Harun"
480 results on '"Ilhan, Harun"'

1. The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on 18F-PSMA-1007 PET

Author

Holzschuh, Julius C., Mix, Michael, Freitag, Martin T., Hölscher, Tobias, Braune, Anja, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K. B., Fechter, Tobias, Kuhn, Dejan, Gratzke, Christian, Grosu, Radu, Grosu, Anca-Ligia, and Zamboglou, C.

Published
2024
Full Text
View/download PDF

4. Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer

Author

Holzschuh, Julius C., Mix, Michael, Ruf, Juri, Hölscher, Tobias, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K.B., Fechter, Tobias, Kuhn, Dejan, Bronsert, Peter, Gratzke, Christian, Grosu, Radu, Kamran, Sophia C., Heidari, Pedram, Ng, Thomas S.C., Könik, Arda, Grosu, Anca-Ligia, and Zamboglou, Constantinos

Published
2023
Full Text
View/download PDF

5. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

Author

Farolfi, Andrea, Ilhan, Harun, Gafita, Andrei, Calais, Jeremie, Barbato, Francesco, Weber, Manuel, Afshar-Oromieh, Ali, Spohn, Fabian, Wetter, Axel, Rischpler, Christoph, Hadaschik, Boris, Pianori, Davide, Fanti, Stefano, Haberkorn, Uwe, Eiber, Matthias, Herrmann, Ken, and Fendler, Wolfgang Peter

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Cancer, Biomedical Imaging, Aging, Prostate Cancer, Aetiology, 2.1 Biological and endogenous factors, Antigens, Surface, Glutamate Carboxypeptidase II, Humans, Image Processing, Computer-Assisted, Lymph Node Excision, Male, Positron-Emission Tomography, Prostatic Neoplasms, Salvage Therapy, Treatment Failure, PET, prostate cancer, PSA persistence, PSMA, salvage lymph node dissection, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvage lymph node dissection (SLND) and pre-procedure and post-procedure prostate-specific membrane antigen (PSMA) ligand PET. Methods: Sixteen patients were included in this multicenter study. The inclusion criteria were PSMA PET performed for biochemical recurrence before SLND (pre-SLND PET) and repeat PSMA PET performed for a persistently elevated PSA level (≥0.1 ng/mL) at least 6 wk after SLND (post-SLND PET). Image analysis was performed by 3 independent nuclear medicine physicians applying the molecular imaging TNM system PROMISE. Lesions were confirmed by histopathology, presence on correlative CT/MRI/bone scanning, or PSA response after focal therapy. Results: Post-SLND PET identified prostate cancer lesions in 88% (14/16) of patients with PSA persistence after SLND. Median PSA was 1.2 ng/mL (interquartile range, 0.6-2.8 ng/mL). Disease was confined to the pelvis in 56% of patients (9/16), and most of these men had common iliac (6/16, 38%) and internal iliac lymph node metastases (6/16, 38%). Extrapelvic disease was detected in 31% of patients (5/16). In pre- and post-SLND PET comparison, 10 of 16 had at least one lesion already detected at baseline (63% PET persistence), 4 of 16 had new lesions only (25% PET recurrence), and 2 had no disease on post-SLND PET. All validated regions (11 regions in 9 patients) were true-positive. Nine of 14 (64%) patients underwent repeat local therapies after SLND (7/14 radiotherapy, 2/14 surgery). Conclusion: SLND of pelvic nodal metastases was often not complete according to PSMA PET. About two thirds of patients had PET-positive nodal disease after SLND already seen on pre-SLND PSMA PET. Notably, about one quarter of patients had new lesions, not detected by presurgical PSMA PET.

Published
2020

8. 68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results

Author

Mittlmeier, Lena M., Todica, Andrei, Gildehaus, Franz-Josef, Unterrainer, Marcus, Beyer, Leonie, Brendel, Matthias, Albert, Nathalie L., Ledderose, Stephan T., Vettermann, Franziska J., Schott, Melanie, Rodler, Severin, Marcon, Julian, Ilhan, Harun, Cyran, Clemens C., Stief, Christian G., Staehler, Michael, and Bartenstein, Peter

Published
2022
Full Text
View/download PDF

10. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

Author

Ahmadzadehfar, Hojjat, Matern, Ralf, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Svirydenka, Hanna, Sathekge, Mike, Kabasakal, Levent, Yordanova, Anna, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene, and Rahbar, Kambiz

Published
2021
Full Text
View/download PDF

11. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours

Author

Beyer, Leonie, Gosewisch, Astrid, Lindner, Simon, Völter, Friederike, Mittlmeier, Lena M., Tiling, Reinhold, Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Rübenthaler, Johannes, Auernhammer, Christoph J., Spitzweg, Christine, Böning, Guido, Gildehaus, F. J., Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Wenter, Vera, Todica, Andrei, Bartenstein, Peter, and Ilhan, Harun

Published
2021
Full Text
View/download PDF

13. Correction to: Value of PET imaging for radiation therapy

Author

Lapa, Constantin, Nestle, Ursula, Albert, Nathalie L., Baues, Christian, Beer, Ambros, Buck, Andreas, Budach, Volker, Bütof, Rebecca, Combs, Stephanie E., Derlin, Thorsten, Eiber, Matthias, Fendler, Wolfgang P., Furth, Christian, Gani, Cihan, Gkika, Eleni, Grosu, Anca-L., Henkenberens, Christoph, Ilhan, Harun, Löck, Steffen, Marnitz-Schulze, Simone, Miederer, Matthias, Mix, Michael, Nicolay, Nils H., Niyazi, Maximilian, Pöttgen, Christoph, Rödel, Claus M., Schatka, Imke, Schwarzenboeck, Sarah M., Todica, Andrei S., Weber, Wolfgang, Wegen, Simone, Wiegel, Thomas, Zamboglou, Constantinos, Zips, Daniel, Zöphel, Klaus, Zschaeck, Sebastian, Thorwarth, Daniela, and Troost, Esther G. C.

Published
2022
Full Text
View/download PDF

15. The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on 18F-PSMA-1007 PET.

Author

Holzschuh, Julius C., Mix, Michael, Freitag, Martin T., Hölscher, Tobias, Braune, Anja, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K. B., Fechter, Tobias, Kuhn, Dejan, Gratzke, Christian, Grosu, Radu, Grosu, Anca-Ligia, and Zamboglou, C.

Subjects
CONVOLUTIONAL neural networks, VOLUMETRIC analysis, POSITRON emission tomography, PROSTATE cancer, STATISTICAL significance
Abstract

Purpose: Convolutional Neural Networks (CNNs) have emerged as transformative tools in the field of radiation oncology, significantly advancing the precision of contouring practices. However, the adaptability of these algorithms across diverse scanners, institutions, and imaging protocols remains a considerable obstacle. This study aims to investigate the effects of incorporating institution-specific datasets into the training regimen of CNNs to assess their generalization ability in real-world clinical environments. Focusing on a data-centric analysis, the influence of varying multi- and single center training approaches on algorithm performance is conducted. Methods: nnU-Net is trained using a dataset comprising 161 18F-PSMA-1007 PET images collected from four distinct institutions (Freiburg: n = 96, Munich: n = 19, Cyprus: n = 32, Dresden: n = 14). The dataset is partitioned such that data from each center are systematically excluded from training and used solely for testing to assess the model's generalizability and adaptability to data from unfamiliar sources. Performance is compared through a 5-Fold Cross-Validation, providing a detailed comparison between models trained on datasets from single centers to those trained on aggregated multi-center datasets. Dice Similarity Score, Hausdorff distance and volumetric analysis are used as primary evaluation metrics. Results: The mixed training approach yielded a median DSC of 0.76 (IQR: 0.64–0.84) in a five-fold cross-validation, showing no significant differences (p = 0.18) compared to models trained with data exclusion from each center, which performed with a median DSC of 0.74 (IQR: 0.56–0.86). Significant performance improvements regarding multi-center training were observed for the Dresden cohort (multi-center median DSC 0.71, IQR: 0.58–0.80 vs. single-center 0.68, IQR: 0.50–0.80, p < 0.001) and Cyprus cohort (multi-center 0.74, IQR: 0.62–0.83 vs. single-center 0.72, IQR: 0.54–0.82, p < 0.01). While Munich and Freiburg also showed performance improvements with multi-center training, results showed no statistical significance (Munich: multi-center DSC 0.74, IQR: 0.60–0.80 vs. single-center 0.72, IQR: 0.59–0.82, p > 0.05; Freiburg: multi-center 0.78, IQR: 0.53–0.87 vs. single-center 0.71, IQR: 0.53–0.83, p = 0.23). Conclusion: CNNs trained for auto contouring intraprostatic GTV in 18F-PSMA-1007 PET on a diverse dataset from multiple centers mostly generalize well to unseen data from other centers. Training on a multicentric dataset can improve performance compared to training exclusively with a single-center dataset regarding intraprostatic 18F-PSMA-1007 PET GTV segmentation. The segmentation performance of the same CNN can vary depending on the dataset employed for training and testing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Author

Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kulkarni, Harshad R, Zhang, Jingjing, Gerke, Carolin, Fimmers, Rolf, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Maffey-Steffan, Johanna, Sathekge, Mike, Kabasakal, Levent, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, and Virgolini, Irene

Published
2021
Full Text
View/download PDF

29. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference

Author

Zamboglou, Constantinos, Fassbender, Thomas F., Steffan, Lina, Schiller, Florian, Fechter, Tobias, Carles, Montserrat, Kiefer, Selina, Rischke, Hans C., Reichel, Kathrin, Schmidt-Hegemann, Nina-Sophie, Ilhan, Harun, Chirindel, Alin F., Nicolas, Guillaume, Henkenberens, Christoph, Derlin, Thorsten, Bronsert, Peter, Mavroidis, Panayiotis, Chen, Ronald C., Meyer, Philipp T., Ruf, Juri, and Grosu, Anca L.

Published
2019
Full Text
View/download PDF

32. Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study

Author

Weber, Manuel, Fendler, Wolfgang P., Ravi Kumar, Aravind S., Calais, Jeremie, Czernin, Johannes, Ilhan, Harun, Saad, Fred, Kretschmer, Alexander, Hekimsoy, Turkay, Brookman-May, Sabine D., Mundle, Suneel D., Small, Eric J., Smith, Matthew R., Perez, Paola M., Hope, Thomas A., Herrmann, Ken, Hofman, Michael S., Eiber, Matthias, and Hadaschik, Boris A.

Published
2024
Full Text
View/download PDF

42. Supplementary Data from Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

Author

Fendler, Wolfgang P., primary, Weber, Manuel, primary, Iravani, Amir, primary, Hofman, Michael S., primary, Calais, Jérémie, primary, Czernin, Johannes, primary, Ilhan, Harun, primary, Saad, Fred, primary, Small, Eric J., primary, Smith, Matthew R., primary, Perez, Paola M., primary, Hope, Thomas A., primary, Rauscher, Isabel, primary, Londhe, Anil, primary, Lopez-Gitlitz, Angela, primary, Cheng, Shinta, primary, Maurer, Tobias, primary, Herrmann, Ken, primary, Eiber, Matthias, primary, and Hadaschik, Boris, primary

Published
2023
Full Text
View/download PDF

43. Immuno-histochemical correlation of fibrosis-related markers with the desmoplastic reaction of the mesentery in small intestine neuroendocrine neoplasms

Author

Bösch, Florian; https://orcid.org/0000-0002-0250-9017, Altendorf-Hofmann, Annelore, Koliogiannis, Vanessa, Ilhan, Harun, Jacob, Sven, Pretzsch, Elise, Nölting, Svenja; https://orcid.org/0000-0002-7064-590X, Werner, Jens, Klauschen, Frederick, Auernhammer, Christoph Josef; https://orcid.org/0000-0001-8087-3722, Angele, Martin K, Knösel, Thomas, Bösch, Florian; https://orcid.org/0000-0002-0250-9017, Altendorf-Hofmann, Annelore, Koliogiannis, Vanessa, Ilhan, Harun, Jacob, Sven, Pretzsch, Elise, Nölting, Svenja; https://orcid.org/0000-0002-7064-590X, Werner, Jens, Klauschen, Frederick, Auernhammer, Christoph Josef; https://orcid.org/0000-0001-8087-3722, Angele, Martin K, and Knösel, Thomas

Abstract

INTRODUCTION Small intestine neuroendocrine neoplasms (siNENs) will attain more importance due to their increasing incidence. Moreover, siNENs might lead to a desmoplastic reaction (DR) of the mesentery causing severe complications and deteriorating prognosis. The expression of fibrosis-related proteins appears to be the key mechanisms for the development of this desmoplastic reaction. Therefore, this study aimed to investigate the association of the desmoplastic mesentery with specific fibrosis-related protein expression levels. MATERIALS AND METHODS By immunohistochemistry, the protein expression levels of four fibrosis-related markers (APLP2, BNIP3L, CD59, DKK3) were investigated in primary tumors of 128 siNENs. The expression levels were correlated with the presence of a desmoplastic reaction and clinico-pathological parameters. RESULTS In the primary tumor, APLP2, BNIP3L, CD59 and DKK3 were highly expressed in 29.7% (n = 38), 64.9% (n = 83), 92.2% (n = 118) and 80.5% (n = 103), respectively. There was no significant correlation of a single marker or the complete marker panel to the manifestation of a desmoplastic mesentery. The desmoplastic mesentery was significantly associated with clinical symptoms, such as flushing and diarrhea. However, neither the fibrosis-related marker panel nor single marker expressions were associated with clinical symptoms. DISCUSSION The expression rates of four fibrosis-related markers in the primary tumor display a distinct pattern. However, the expression patterns are not associated with desmoplastic altered mesenteric lymph node metastases and the expression patterns did not correlate with prognosis. These findings suggest alternative mechanisms being responsible for the desmoplastic reaction.

Published
2023

44. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study

Author

Ilhan, Harun, Kroenke, Markus, Wurzer, Alexander, Unterrainer, Marcus, Heck, Matthias, Belka, Claus, Knorr, Karina, Langbein, Thomas, Rauscher, Isabel, Schmidt-Hegemann, Nina-Sophie, Schiller, Kilian, Bartenstein, Peter, Wester, Hans-Jürgen, and Eiber, Matthias

Subjects
Radiology, Nuclear Medicine and imaging, Clinical Investigation
Abstract

This bicentric, retrospective analysis investigated the efficacy of PET/CT with a novel theranostic prostate-specific membrane antigen (PSMA)--targeting ligand, (18)F-rhPSMA-7, in patients with biochemical recurrence (BCR) of prostate cancer after curative-intent primary radiotherapy. Methods: Datasets from patients with BCR of prostate cancer after external-beam radiation therapy or brachytherapy who underwent (18)F-rhPSMA-7 PET/CT at either Technical University Munich or Ludwig-Maximilians-University Munich were retrospectively reviewed by experienced nuclear medicine physicians and radiologists at both centers. The median injected activity was 299 MBq (range, 204–420 MBq), and the median uptake time was 77 min (range, 46–120 min). All lesions suggestive of recurrent prostate cancer were noted. Detection rates were correlated with patients’ prostate-specific antigen (PSA) level, primary Gleason score, and prior use of androgen-deprivation therapy (ADT). Results: Ninety-seven patients were included (65 at Technical University Munich and 32 at Ludwig-Maximilians-University Munich). The median prescan PSA was 4.19 ng/mL (range, 0.1–159 ng/mL). The primary Gleason score was ≤6 in 19 patients, 7 in 25, ≥8 in 33, and unknown in 20. Thirty patients received ADT in the 6 mo preceding PET/CT. (18)F-rhPSMA-7 identified lesions in 91 of 97 (94%) patients. Detection rates stratified by PSA were 88% (22/25), 97% (30/31), 90% (19/21), and 100% (20/20) for a PSA of

Published
2022

48. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Author

Eschbach, Ralf S., primary, Hofmann, Markus, additional, Späth, Lukas, additional, Sheikh, Gabriel T., additional, Delker, Astrid, additional, Lindner, Simon, additional, Jurkschat, Klaus, additional, Wängler, Carmen, additional, Wängler, Björn, additional, Schirrmacher, Ralf, additional, Tiling, Reinhold, additional, Brendel, Matthias, additional, Wenter, Vera, additional, Dekorsy, Franziska J., additional, Zacherl, Mathias J., additional, Todica, Andrei, additional, Ilhan, Harun, additional, Grawe, Freba, additional, Cyran, Clemens C., additional, Unterrainer, Marcus, additional, Rübenthaler, Johannes, additional, Knösel, Thomas, additional, Paul, Tanja, additional, Boeck, Stefan, additional, Westphalen, Christoph Benedikt, additional, Spitzweg, Christine, additional, Auernhammer, Christoph J., additional, Bartenstein, Peter, additional, Unterrainer, Lena M., additional, and Beyer, Leonie, additional

Published
2023
Full Text
View/download PDF

49. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors

Author

Zellmer, Johannes, primary, Yen, Hsi-Yu, additional, Kaiser, Lena, additional, Gildehaus, Franz Josef, additional, Böning, Guido, additional, Steiger, Katja, additional, Hacker, Marcus, additional, Bartenstein, Peter, additional, Todica, Andrei, additional, Haug, Alexander R., additional, and Ilhan, Harun, additional

Published
2022
Full Text
View/download PDF

50. Additional file 1 of Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition

Author

Resch, Sandra, Takayama Fouladgar, Sarah, Zacherl, Mathias, Sheikh, Gabriel T., Liubchenko, Grigory, Rumiantcev, Mikhail, Unterrainer, Lena M., Wenter, Vera, Bartenstein, Peter, Ziegler, Sibylle I., Ilhan, Harun, Beyer, Leonie, Böning, Guido, and Delker, Astrid

Abstract

Additional file 1. Supplementary data plots as referenced in the main text.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results